UNSPSC 51411504: Hexobendine

This classification denotes a vasodilating agent with the molecular formula C30H44N2O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B6X4SYR93B, chemically known as 3,4,5-trimethoxybenzoic acid, diester with 3,3-(ethylenebis(methylimino))di-1-propanol but generally known as hexobendine, which bears US NIH Compound Identifier 5777. European Medicines Agency schedules Hexobendine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08039MIG. The term HEXOBENDINE is an International Non-Proprietary Name.

UNSPSC 51411504 Hexobendine is a Commodity code that captures emergency pharmaceuticals and specialty medications procured by state and local health systems, fire rescue services, and pharmacy benefit programs. Recent state and local solicitations under this code center on advanced life support medications, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription fulfillment programs. The work involves supplying branded and generic medications with strict quality, expiration, and regulatory compliance requirements — including cGMP certification, DSCSA compliance, OSHA Safety Data Sheets, and FDA approval. Issuing bodies include city fire rescue departments (Tampa Fire Rescue via the City of Tampa's Purchasing Department), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of participating state and local government facilities across multiple jurisdictions including Oregon). Vendors typically work through authorized wholesalers and must maintain comprehensive insurance, manage cold-chain or expiration logistics, and demonstrate pricing flexibility across multiple net-price formats.

Recent activity spans Florida, Texas, and Minnesota-led cooperative purchasing. The City of Tampa Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, Diltiazem vials) with a response date of April 8, 2026 and an estimated contract value of $40,000, including a 5 percent Small Local Business Enterprise (SLBE) discount incentive. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program — a market-intelligence phase prior to formal procurement. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 (response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products, requiring vendors to work through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson) with contract terms beginning July 1, 2026. Performance penalties ranging from $200 to $1,500 per violation apply under MMCAP, and vendors must pay a 3 percent administrative fee on all purchases.